Larotrectinib

Lung Cancer

Sun Yat-sen UniversitySmall moleculePhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 89/ 100

Competitive context

298 Active assets in the Lung Cancer cohort.

Asset / Sponsor	Phase	Rating
Cis-Diamminedichloroplatinum Ii University of Vermont	Phase 4	BB
Carboplatin SystImmune Inc.	Phase 4	BB
Desflurane Peter MacCallum Cancer Centre, Australia	Phase 4	BB
Etoposide SystImmune Inc.	Phase 3	BB
Nivolumab University of Chicago	Phase 4	BB

View all 50 →

Same molecule, other indications

Larotrectinib is also rated in:

NTRK fusion positive cancerActive

BB

Indicative · Phase 1/2

65 / 100

non-Hodgkin lymphomaActive

CCC

Indicative · Phase 2

53 / 100

refractory malignant neoplasmActive

CCC

Indicative · Phase 2

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.